Bresesti Chiara, Vezzoli Valeria, Cangiano Biagio, Bonomi Marco
Department of Endocrine and Metabolic Medicine, IRCCS Istituto Auxologico Italiano, Milan, Italy.
Lab of Endocrine and Metabolic Researches, IRCCS Istituto Auxologico Italiano, Cusano Milanino, Italy.
Front Oncol. 2021 Mar 9;11:605606. doi: 10.3389/fonc.2021.605606. eCollection 2021.
In the last few years lncRNAs have gained increasing attention among the scientific community, thanks to the discovery of their implication in many physio-pathological processes. In particular, their contribution to tumor initiation, progression, and response to treatment has attracted the interest of experts in the oncologic field for their potential clinical application. Testicular cancer is one of the tumors in which lncRNAs role is emerging. Said malignancies already have very effective treatments, which although lead to the development of quite serious treatment-related conditions, such as secondary tumors, infertility, and cardiovascular diseases. It is therefore important to study the impact of lncRNAs in the tumorigenesis of testicular cancer in order to learn how to exploit them in a clinical setting and to substitute more toxic treatments. Eventually, the use of lncRNAs as biomarkers, drug targets, or therapeutics for testicular cancer may represent a valid alternative to that of conventional tools, leading to a better management of this malignancy and its related conditions, and possibly even to the treatment of poor prognosis cases.
在过去几年中，长链非编码RNA（lncRNAs）在科学界受到越来越多的关注，这得益于其在许多生理病理过程中的作用被发现。特别是，它们对肿瘤起始、进展和治疗反应的贡献因其潜在的临床应用而引起了肿瘤学领域专家的兴趣。睾丸癌是lncRNAs作用正在显现的肿瘤之一。上述恶性肿瘤已经有非常有效的治疗方法，尽管这些治疗会导致相当严重的与治疗相关的病症，如继发性肿瘤、不育症和心血管疾病。因此，研究lncRNAs在睾丸癌肿瘤发生中的影响，以便了解如何在临床环境中利用它们并替代毒性更大的治疗方法，这一点很重要。最终，将lncRNAs用作睾丸癌的生物标志物、药物靶点或治疗方法，可能是传统工具的有效替代方案，从而更好地管理这种恶性肿瘤及其相关病症，甚至可能治疗预后不良的病例。
